| Drug General Information |
| Drug ID |
D03ONZ
|
| Former ID |
DIB008942
|
| Drug Name |
MCS-18
|
| Synonyms |
Helleborus purpurascens-derived anti-inflammatory analgesic (injection, autoimmune disease), DoNatur
|
| Indication |
Autoimmune diabetes [ICD10:E08-E13]
|
Phase 2 |
[1]
|
|---|
| Company |
DoNatur GmbH
|
| Structure |
|
Download
2D MOL
|
| Canonical SMILES |
c12c3oc4c(C1)oc1c(=O)c5c(c(=O)c6c(o5)c(=O)c(c(o6)c3=O)o<br />2)oc1c4=O
|
| Target and Pathway |
| Target(s) |
Toll-like receptor 2 |
Target Info |
Modulator |
[1]
|
|---|
|
KEGG Pathway
|
Phagosome
|
|
PI3K-Akt signaling pathway
|
|
Toll-like receptor signaling pathway
|
|
Legionellosis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
Malaria
|
|
Toxoplasmosis
|
|
Amoebiasis
|
|
Tuberculosis
|
|
Hepatitis B
|
|
Measles
|
|
Herpes simplex infection
|
|
Proteoglycans in cancer
|
|
Inflammatory bowel disease (IBD)
|
|
Rheumatoid arthritis
|
|
NetPath Pathway
|
IL4 Signaling Pathway
|
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Toll receptor signaling pathway
|
|
Pathway Interaction Database
|
Endogenous TLR signaling
|
|
Reactome
|
Beta defensins
|
|
MyD88:Mal cascade initiated on plasma membrane
|
|
Toll Like Receptor TLR6:TLR2 Cascade
|
|
MyD88 deficiency (TLR2/4)
|
|
IRAK4 deficiency (TLR2/4)
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
IL1 and megakaryotyces in obesity
|
|
Human Complement System
|
|
Toll-Like Receptors Cascades
|
|
MyD88:Mal cascade initiated on plasma membrane
|
|
Defensins
|
|
Regulation of toll-like receptor signaling pathway
|
| References |
| REF 1 | The novel arthritis-drug substance MCS-18 attenuates the antibody production in vivo. Acta Microbiol Immunol Hung. 2008 Mar;55(1):15-31. |
|---|
